首页> 外文期刊>The Journal of Immunology: Official Journal of the American Association of Immunologists >Tax and M1 Peptide/HLA-2A-Specific Fabs and T Cell Receptors Recognize Nonidentical Structural Features on Peptide/HLA-A2 Complexes
【24h】

Tax and M1 Peptide/HLA-2A-Specific Fabs and T Cell Receptors Recognize Nonidentical Structural Features on Peptide/HLA-A2 Complexes

机译:Tax和M1肽/ HLA-2A特异的Fab和T细胞受体识别肽/ HLA-A2络合物的结构特征不同

获取原文
获取原文并翻译 | 示例
           

摘要

Both TCRs and Ab molecules are capable of MHC-restricted recognition of peptide/MHC complexes. However, such MHC restriction is the predominant mode of recognition by t cells, but is extremely rare for B cells. The present study asks whether the dichotomy in Ag recognition modes of T and B cells could be due to fundamental differences in the methods by which TCRs and Abs recognize peptide/MHC complexes.We have compared MHC and peptide recognition by panels of CTL lines specific for the Tax and M1 peptides presented by HLA-A2 plus Tax and M1 peptide/HLA-A2-specific human Fabsd that were selected from a naive phase display library. Collectively, the results indicate both striking similarities and important differences between Fab and TCR recognition of MHC and peptide components of the Tax and M1/HLA-A2 complexes.These findings suggest that these two classes of immunorceptors have solved the problem of specific recognition of peptide/MHC complexes by nonidentical mechanisms.This conclusion is important in part because it indicates that Ab engineering approaches could produce second-generation Ab molecules that more closely mimic TCR fine specificity.Such efforts may produce more efficacious diagnostic and therapeutic agents.
机译:TCR和Ab分子均能够通过MHC限制识别肽/ MHC复合物。但是,这种MHC限制是t细胞识别的主要方式,但对于B细胞却极为罕见。本研究询问T细胞和B细胞在Ag识别模式上的二分法是否可能是由于TCR和Abs识别肽/ MHC复合物的方法的根本差异所致。从天真相展示库中选择的HLA-A2所提供的Tax和M1肽加上Tax和M1肽/ HLA-A2特异性人Fabsd。总的来说,结果表明Fab和TCR对MHC的识别以及Tax和M1 / HLA-A2复合物的肽组分之间既有惊人的相似又有重要区别,这些发现表明这两类免疫受体解决了对肽的特异性识别的问题。 / MHC通过不同的机制复合。这一结论之所以重要,部分原因在于它表明Ab工程学方法可以产生更紧密地模仿TCR精细特异性的第二代Ab分子,这些努力可能会产生更有效的诊断和治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号